An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)

MLA

Michael Robert Migden, et al. “An Open-Label, Multicenter, Phase 1b/2 Study of RP1, a First-in-Class, Enhanced Potency Oncolytic Virus in Solid Organ Transplant Recipients with Advanced Cutaneous Malignancies (ARTACUS).” Journal of Clinical Oncology, vol. 40, June 2022, p. TPS9597. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.tps9597.

APA

Michael Robert Migden, Jason J. Luke, Wanxing Chai-Ho, Meenal Kheterpal, Trisha Michel Wise-Draper, Andrew Stewart Poklepovic, Diana Bolotin, Claire F. Verschraegen, Frances A. Collichio, Jennifer Tang, Gregory A. Daniels, Katy K. Tsai, Susan Benedict Navia, Haifeng Zhang, & Christoph Matthias Ahlers. (2022). An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS). Journal of Clinical Oncology, 40, TPS9597. https://doi.org/10.1200/jco.2022.40.16_suppl.tps9597

Chicago

Michael Robert Migden, Jason J. Luke, Wanxing Chai-Ho, Meenal Kheterpal, Trisha Michel Wise-Draper, Andrew Stewart Poklepovic, Diana Bolotin, et al. 2022. “An Open-Label, Multicenter, Phase 1b/2 Study of RP1, a First-in-Class, Enhanced Potency Oncolytic Virus in Solid Organ Transplant Recipients with Advanced Cutaneous Malignancies (ARTACUS).” Journal of Clinical Oncology 40 (June): TPS9597. doi:10.1200/jco.2022.40.16_suppl.tps9597.